Kategorie: Allgemein

STOCKHOLM, SWEDEN, – October 26, 2022 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that a new clinical study has been published presenting the improvement that the Nevisense test provides over standard of care visual and dermoscopic evaluation. The article named “Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin… New study shows Nevisense significantly improves US clinician’s decision-making beyond dermoscopy weiterlesen

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company nominating committee which were determined at the Annual General Meeting of SciBase Holding on May 18, 2022. The Annual General Meeting of SciBase Holding AB (publ) will be held on May 18, 2023 in Stockholm. Shareholders who… The following people have been appointed as members of SciBase Holding’s nominating committee for the Annual General Meeting in 2023: weiterlesen

The use of professional and household cleaning agents is associated with an increased risk of developing allergic disorders. In line with this, impairment of the epithelial barrier is also associated with the development of allergic disorders. The aim of the study was to utilize Nevisense and Electrical Impedance Spectroscopy (EIS) to assess the effect of… Nevisense detects skin barrier damage in mice caused by household detergents weiterlesen

Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for more high quality research to validate these technologies. „The standards would have to be set very high for new products, especially those intended for consumers,“ said FDA panelist Murad Alam, MD, a dermatologist from Northwestern University, Chicago, Illinois. The… FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers weiterlesen

The aim of the study was to investigate the impact Electrical Impedance Spectroscopy (EIS) has on clinical decision-making for atypical pigmented skin lesions (PSLs) when compared to other diagnostic tools such as dermoscopy. Dermatologists, dermatology residents, and medical students completed an online survey eliciting their biopsy decisions for 24 atypical PSLs of varying histopathological diagnosis.… US study shows that EIS and Nevisense significantly improves clinicians’ diagnostic accuracy weiterlesen

The first quarter in figures Net sales amounted to TSEK 4,260 (2,562). The loss after tax amounted to TSEK 9,736 (8,153). The loss per share amounted to SEK 0.14 (0.15). The cash flow from current operations was negative in the amount of TSEK 10,512 (9,473). The gross margin reached 62.8% (52.7%). Electrode sales volume increased by 33% and reached… Interim Report Q1 2022 weiterlesen

„It has been a busy start to the year and we see an exciting year in front of us with US growth and progress with the skin barrier application.,“ says Simon Grant, CEO SciBase. For more information please contact:Simon Grant, CEO SciBase Tel: +46 72 887 43 99 Email:   Certified Advisor:Vator Securities Tel: +46 8 580 065… SciBase to present at the Redeye Medtech & Diagnostics Seminar on May 11, 2022 weiterlesen

The study looked at the real-life clinical effectiveness of Electrical Impedance Spectroscopy (EIS) when using Nevisense to detect malignancies in an everyday clinical setting. In summary, the study clinic showed a reduction in the number of unnecessary excisions of 47%, while still detecting 100% of melanomas. Clinicians combine Nevisense with visual and dermatoscopic examinations to… German study shows clinical benefit of Nevisense weiterlesen

A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFO Tel: +46 70 341 34 72 E-mail: Certified Advisor: Vator Securities Tel: +46 580 065 99 Email: The… SciBase publishes the Annual report for 2021 weiterlesen

In addition, SciBase was granted their first patent within the skin barrier area in Sweden in November. This patent named `Epithelial barrier function‘ with application no 1851376-2, was granted by the Swedish patent authority and is seen as a positive indication that an EPO patent will also eventually be granted. „An early focus on intellectual property from the SciBase… SciBase further strengthens patent portfolio weiterlesen